Akums Drugs Share Price: ₹134 Crore ka Tax Ka Chakkar, Stock Mein Giri

BANKINGFINANCE
Whalesbook Logo
AuthorKavya Nair|Published at:
Akums Drugs Share Price: ₹134 Crore ka Tax Ka Chakkar, Stock Mein Giri
Overview

Bhai log, Akums Drugs aur uski subsidiary Akumentis Healthcare ko income tax department se ₹134 crore ka notice mila hai. Ye 2018 se 2025 tak ke kharchon ko disallowed karne par hai. Company bol rahi hai ki wo appeal karegi aur isse koi bada financial impact nahi hoga. News aate hi stock thoda neeche aa gaya.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Income Tax Ka Bada Panga

Akums Drugs aur uski subsidiary Akumentis Healthcare ko Delhi ke Deputy Commissioner of Income Tax se total ₹133.75 crore ka tax assessment order mila hai. Ye demand April 1, 2018 se March 12, 2025 tak ke period ke liye hai. Ismein Akums Drugs ka hissa ₹60.09 crore hai aur Akumentis Healthcare ka ₹73.66 crore hai. Tax department ne Income Tax Act, 1961 ke Section 37(1) ke tehat kai kharchon ko allow nahi kiya, isi wajah se ye demand nikli hai.

Company Ka Plan: Appeal Aur No Major Impact

Akums Drugs ka kehna hai ki internal review ke baad unhe lagta hai ki ye tax orders unke finances par zyada asar nahi daalenge. Unhe vishwas hai ki ye demands legal basis par khadi nahi hoti aur iske liye wo proper appeal file karenge. Ye kuch January 2025 mein hue income tax search ke waqt ki situation jaisi hi hai, jab bhi company ne cooperation dikhaya tha aur stock price thoda gira tha.

Stock Market Ka Reaction Aur Valuation

Wednesday, May 20, 2026 ko Akums Drugs and Pharmaceuticals Ltd. ka stock 1.29% neeche girkar ₹513.00 par close hua. Tax demand ki khabar aane ke baad ye movement dekha gaya. Company ki market cap lagbhag ₹8,100 crore hai. Iska P/E ratio 26.4x se 73.3x ke beech hai, jo industry peers aur Asian Life Sciences ke average 37.4x aur 36.2x ke comparison mein theek lag raha hai. FY 2025-2026 mein company ka revenue ₹4,359 crore tha aur profit after tax ₹256.4 crore, jo pichhle saal se 25% kam hai.

Regulatory Environment Aur Pichhle Incidents

India mein pharma sector kaafi strict regulatory environment mein chalta hai, jismein Central Drugs Standard Control Organization (CDSCO) jaise bodies ka oversight hota hai. Ye regulations drug quality aur safety ke liye hain, lekin compliance mein challenges bhi la sakte hain. January 2025 mein hue income tax search se market ki sensitivity dikhi thi, jismein stock price 6-7% tak gira tha. Abhi ki demands bhi isi tax authorities ki examination se nikli hain.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.